S-1

A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

Isamu Okamoto, Masahiro Fukuoka

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalClinical Lung Cancer
Volume10
Issue number4
DOIs
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
irinotecan
gemcitabine
Platinum Compounds
Tegafur
Tokyo
Pancreatic Neoplasms
Uterine Cervical Neoplasms
Stomach Neoplasms
Colorectal Neoplasms
Japan
Therapeutics
Clinical Trials
Breast Neoplasms
Safety
Research
Pharmaceutical Preparations
Neoplasms
gimeracil
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

S-1 : A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. / Okamoto, Isamu; Fukuoka, Masahiro.

In: Clinical Lung Cancer, Vol. 10, No. 4, 01.01.2009, p. 290-294.

Research output: Contribution to journalReview article

@article{ce1c2dc4044f4c189e19801fb7f4b75e,
title = "S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer",
abstract = "S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.",
author = "Isamu Okamoto and Masahiro Fukuoka",
year = "2009",
month = "1",
day = "1",
doi = "10.3816/CLC.2009.n.040",
language = "English",
volume = "10",
pages = "290--294",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - S-1

T2 - A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

AU - Okamoto, Isamu

AU - Fukuoka, Masahiro

PY - 2009/1/1

Y1 - 2009/1/1

N2 - S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.

AB - S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=70349446637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349446637&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.040

DO - 10.3816/CLC.2009.n.040

M3 - Review article

VL - 10

SP - 290

EP - 294

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -